Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model

Molecular Therapy

Volumn 24, Issue 2, 2016, Pages 364-374

  Lu, Yao ^a,b   Miao, Lei ^a   Wang, Yuhua ^a   Xu, Zhenghong ^a   Zhao, Yi ^a   Shen, Youqing ^c   Xiang, Guangya ^b   Huang, Leaf ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; GAMMA INTERFERON; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDE VACCINE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; CANCER VACCINE; MACROGOL DERIVATIVE; MICELLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; IN VIVO STUDY; MELANOMA; MICELLE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR MICROENVIRONMENT; ANIMAL; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENE EXPRESSION REGULATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA, EXPERIMENTAL; SIGNAL TRANSDUCTION;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CURCUMIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MELANOMA, EXPERIMENTAL; MICE; MICELLES; POLYETHYLENE GLYCOLS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84959552204     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.165     Document Type: Article

References (49)

1. Blattman, JN and Greenberg, PD (2004). Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
2. Haanen, JB (2013). Immunotherapy of melanoma. EJC Suppl 11: 97-105.
3. Vasievich, EA and Huang, L (2011). The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm 8: 635-641.
4. Rabinovich, GA, Gabrilovich, D and Sotomayor, EM (2007). Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
5. Xu, Z, Wang, Y, Zhang, L and Huang, L (2014). Nanoparticle-Delivered transforming growth factor-βsiRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 8: 3636-3645.
6. Draghiciu, O, Lubbers, J, Nijman, HW and Daemen, T (2015). Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology 4: e954829.
7. Talmadge, JE and Gabrilovich, DI (2013). History of myeloid-Derived suppressor cells. Nat Rev Cancer 13: 739-752.
8. Ozao-Choy, J, Ma, G, Kao, J, Wang, GX, Meseck, M, Sung, M, et al. (2009). The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69: 2514-2522.
9. Molavi, O, Ma, Z, Hamdy, S, Lai, R, Lavasanifar, A and Samuel, J (2008). Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunol Cell Biol 86: 506-514.
10. Yu, H, Pardoll, D and Jove, R (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
11. Lee, H, Pal, SK, Reckamp, K, Figlin, RA and Yu, H (2011). STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol 344: 41-59.
12. Yu, H, Lee, H, Herrmann, A, Buettner, R and Jove, R (2014). Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14: 736-746.
13. Tu, SP, Jin, H, Shi, JD, Zhu, LM, Suo, Y, Lu, G, et al. (2012). Curcumin induces the differentiation of myeloid-Derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) 5: 205-215.
14. Mondal, G, Barui, S, Saha, S and Chaudhuri, A (2013). Tumor growth inhibition through targeting liposomally bound curcumin to tumor vasculature. J Control Release 172: 832-840.
15. Hayakawa, T, Sugiyama, J, Yaguchi, T, Imaizumi, A and Kawakami, Y (2014). Enhanced anti-Tumor effects of the PD-1/PD-L1 blockade by combining a highly absorptive form of NF-kB/STAT3 inhibitor curcumin. J Immunother Cancer 2: P210.
16. Anand, P, Sundaram, C, Jhurani, S, Kunnumakkara, AB and Aggarwal, BB (2008). Curcumin and cancer: an 'old-Age' disease with an 'age-old' solution. Cancer Lett 267: 133-164.
17. Wilken, R, Veena, MS, Wang, MB and Srivatsan, ES (2011). Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 10: 12.
18. Jagetia, GC and Aggarwal, BB (2007). 'Spicing up' of the immune system by curcumin. J Clin Immunol 27: 19-35.
19. Singh, M, Ramos, I, Asafu-Adjei, D, Quispe-Tintaya, W, Chandra, D, Jahangir, A, et al. (2013). Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med 2: 571-582.
20. Luo, F, Song, X, Zhang, Y and Chu, Y (2011). Low-Dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity. Int Immunopharmacol 11: 1234-1240.
21. Lu, Y, Ding, N, Yang, C, Huang, L, Liu, J and Xiang, G (2012). Preparation and in vitro evaluation of a folate-linked liposomal curcumin formulation. J Liposome Res 22: 110-119.
22. Anand, P, Nair, HB, Sung, B, Kunnumakkara, AB, Yadav, VR, Tekmal, RR, et al. (2010). Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 79: 330-338.
23. Lin, YL, Liu, YK, Tsai, NM, Hsieh, JH, Chen, CH, Lin, CM, et al. (2012). A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcuminsensitive and curcumin-resistance cells. Nanomedicine 8: 318-327.
24. Bisht, S, Mizuma, M, Feldmann, G, Ottenhof, NA, Hong, SM, Pramanik, D, et al. (2010). Systemic administration of polymeric nanoparticle-Encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther 9: 2255-2264.
25. Tang, H, Murphy, CJ, Zhang, B, Shen, Y, Sui, M, Van Kirk, EA, et al. (2010). Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. Nanomedicine (Lond) 5: 855-865.
26. Murphy, CJ, Tang, H, Van Kirk, EA, Shen, Y and Murdoch, WJ (2012). Reproductive effects of a pegylated curcumin. Reprod Toxicol 34: 120-124.
27. Torchilin, V (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63: 131-135.
28. Maeda, H, Wu, J, Sawa, T, Matsumura, Y and Hori, K (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284.
29. Fang, J, Nakamura, H and Maeda, H (2011). The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved and limitations and augmentation of the effect. Adv Drug Deliv Rev 63: 136-151.
30. Xu, Z, Ramishetti, S, Tseng, YC, Guo, S, Wang, Y and Huang, L (2013). Multifunctiona nanoparticles co-Delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release 172: 259-265.
31. Wen, YJ, Min, R, Tricot, G, Barlogie, B and Yi, Q (2002). Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99: 3280-3285.
32. Pan, PY, Ozao, J, Zhou, Z and Chen, SH (2008). Advancements in immune tolerance. Adv Drug Deliv Rev 60: 91-105.
33. Stetson, DB and Medzhitov, R (2006). Type I interferons in host defense. Immunity 25: 373-381.
34. Burkholder, B, Huang, RY, Burgess, R, Luo, S, Jones, VS, Zhang, W, et al. (2014). Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 1845: 182-201.
35. Bracci, L, Schiavoni, G, Sistigu, A and Belardelli, F (2014). Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21: 15-25.
36. Mantovani, A, Sica, A and Locati, M (2005). Macrophage polarization comes of age. Immunity 23: 344-346.
37. Schwartz, YSh and Svistelnik, AV (2012). Functional phenotypes of macrophages and the M1-M2 polarization concept. Part I. Proinflammatory phenotype. Biochemistry Mosc 77: 246-260.
38. Davis, MJ, Tsang, TM, Qiu, Y, Dayrit, JK, Freij, JB, Huffnagle, GB, et al. (2013). Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio 4: e00264-E00213.
39. Whiteside, TL (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912.
40. Chang, YF, Chuang, HY, Hsu, CH, Liu, RS, Gambhir, SS and Hwang, JJ (2012). Immunomodulation of curcumin on adoptive therapy with T cell functional imaging in mice. Cancer Prev Res (Phila) 5: 444-452.
41. Yu, H, Kortylewski, M and Pardoll, D (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41-51.
42. Kunnumakkara, AB, Anand, P and Aggarwal, BB (2008). Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269: 199-225.
43. Gajewski, TF, Schreiber, H and Fu, YX (2013). Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14: 1014-1022.
44. Bowman, T, Broome, MA, Sinibaldi, D, Wharton, W, Pledger, WJ, Sedivy, JM, et al. (2001). Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 98: 7319-7324.
45. Gritsko, T, Williams, A, Turkson, J, Kaneko, S, Bowman, T, Huang, M, et al. (2006). Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12: 11-19.
46. Marotta, LL, Almendro, V, Marusyk, A, Shipitsin, M, Schemme, J, Walker, SR, et al. (2011). The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24-stem cell-like breast cancer cells in human tumors. J Clin Invest 121: 2723-2735.
47. Sumimoto, H, Imabayashi, F, Iwata, T and Kawakami, Y (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203: 1651-1656.
48. Zheng, SG, Wang, J, Wang, P, Gray, JD and Horwitz, DA (2007). IL-2 is essential for TGF-beta to convert naive CD4+CD25-cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 178: 2018-2027.
49. Wang, L, Shen, Y, Song, R, Sun, Y, Xu, J and Xu, Q (2009). An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol Pharmacol 76: 1238-1245.